Short Interest in Apollomics, Inc. (NASDAQ:APLM) Increases By 34.9%

Apollomics, Inc. (NASDAQ:APLM) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 209,300 shares, an increase of 34.9% from the March 31st total of 155,100 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 191,500 shares, the days-to-cover ratio is currently 1.1 days.

Apollomics Stock Performance

Apollomics stock traded down $0.02 during mid-day trading on Friday, hitting $0.45. The company’s stock had a trading volume of 245,270 shares, compared to its average volume of 183,745. The company has a 50 day moving average of $0.62 and a 200-day moving average of $0.84. Apollomics has a one year low of $0.40 and a one year high of $6.45.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC purchased a new stake in Apollomics, Inc. (NASDAQ:APLM) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics at the end of the most recent reporting period. Institutional investors and hedge funds own 19.13% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright dropped their target price on shares of Apollomics from $17.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, April 1st.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.